Comment by European Alzheimer’s Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer’ s disease

Jessen, F., Arbizu, J., Boada, M., Balasa, M., Bennys, K., Boban, M., Bürger, K., Chincarini, A., Cagnin, A., De Deyn, P. P., Düzel, E., Engelborghs, S., Ewers, M., Exalto, L. G., van der Flier, W. M., Fortea, J., Frederiksen, K. S., Frisoni, G. B., Frölich, L., et al. (2025). Comment by European Alzheimer’s Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer’ s disease. The Journal of Prevention of Alzheimer’s Disease, 12(8), 100259. https://doi.org/10.1016/j.tjpad.2025.100259 (Original work published 2025)